Transforming growth factor beta (TGF beta(1)) influences a host of cellular fates, including proliferation, migration, And differentiation. Due to its short half-life and cross reactivity with a variety of cells, clinical application of TGF beta(1) may benefit from a localized delivery strategy. Photoencapsulation of proteins in polymeric matrices. offers such an opportunity; however, the reactions forming polymer networks often result in lowered protein bioactivity. Here, PEG-based gels formed from the chain polymerization of acrylated monomers were studied as a model system for TGF beta(1) delivery. Concentrations. of acrylate group ranging from 0 to 50 mM and photopolymerization conditions were systematically altered to study their effects on TGF beta(1).. bioactivity. In addition, two peptide sequences,.WSHW (K-D = 8.20 nM) and IcRiwpipRsswy (KD = 10.41 nM), that exhibit. binding affinity for TGF beta(1) were introduced into the monomer solution prior to encapsulation to determine if affinity binders would. increase the activity and release of the encapsulated growth factor. The addition of affinity peptides enhanced the bioactivity of. TGF beta(1) in vitro from 1.3- to 2.9-fold, compared to hydrogels with no peptide. Further, increasing the concentration of affinity peptides by a factor of 100-10000 relative to the TGF beta(1) concentration increased fractional recovery of the protein from PEG hydrogels.